Startups

Seed Financing for Deep Tech Startups: What Changes and What to Ask

Seed Financing for Deep Tech Startups, a Founders Form Insights article, with a portrait of Omed Sharifi

A seed round for a deep tech or life sciences startup uses the same instruments as any other seed round, usually SAFEs or Series Seed preferred stock, but investors are buying something different. A software company raises on users and revenue. A robotics, hardware or biotech company raises on technical milestones, and on proof that the company actually owns the technology it is built on. That moves the legal work. Intellectual property ownership, any university or lab license, the terms attached to grant money, and a round sized to reach the next technical milestone all matter more than they would in a typical software seed. Good seed counsel for a deep tech company has closed venture financings before and will look hard at those four things before investors do.

This guide covers what is different about a deep tech seed round, the IP and licensing questions investors will ask, how grants and venture money interact, how these rounds tend to be structured, and what to ask a lawyer before you hire one.

In this guide

Investors fund milestones, not metrics

A software startup can show traction within months: sign-ups, retention, revenue. A company building a drug, a robot or a new material often cannot show revenue for years. What it can show is evidence, one stage at a time, that the technology works.

On the Founders Form Podcast, Omed Sharifi described how that changes the conversation with investors. For a biopharma company, the path runs from a hypothesis and proof of concept, to preclinical validation, to an investigational new drug application, and then through clinical phases. For robotics, he put the questions this way:

"Can this robot actually work? Is it repeatable? Is it accurate? Does it work outside of a laboratory environment?"

Then come manufacturing and deployment: whether the product can be built well at scale. The point, in his words, is that at each milestone you are trying to "illustrate more evidence that your idea will be accepted and scale."

Diagram: what each funding round pays for. Software moves from a working product to early users and revenue, repeatable growth and scaling. Biotech moves from proof of concept to preclinical validation, IND filing and Phase 1, then Phase 2 and pivotal data. Robotics and hardware move from a lab prototype to working outside the lab, pilot deployments and manufacturing at scale.

This has two practical consequences for a seed round. First, the amount you raise should be tied to a specific milestone that the next investor will recognize, with a buffer, because technical work tends to run long. Second, different investors fund different stages. A seed investor comfortable with technical risk may not be the investor who funds manufacturing or a clinical trial, so the terms you agree to now need to leave room for the investors who come next.

Who owns the IP

In a deep tech company, the intellectual property is most of what an investor is buying. Before a seed investor wires money, their lawyers will ask the company to show that it owns or has the right to use every piece of its core technology. As Omed put it on the podcast:

"They're not just investing in the founders. They're investing in the ideas, and the ideas can belong to people if they do not sign that IP assignment."

The usual problem areas:

  • Founders. Work done before the company existed does not belong to the company until it is assigned in writing. Each founder should sign an invention assignment covering what they built before and after incorporation.
  • Prior employers and universities. Employment agreements and university IP policies often claim inventions made with the institution's time, funding or facilities. A founder who developed the technology as a graduate student, postdoc or employee may not own it personally, which means they cannot assign it to the company. This needs to be checked against the actual policy or agreement, not assumed.
  • Employees, contractors and advisors. Everyone who contributed to the technology should have signed an agreement assigning their work to the company. Work done by a contractor without a written assignment can remain the contractor's property.
  • Disclosure before filing. Publishing a paper, presenting at a conference, or sharing technical details in a pitch before a patent application is filed can limit or end patent rights in many countries. The United States allows a one-year grace period for an inventor's own disclosures. Most other jurisdictions do not. Investors rarely sign confidentiality agreements, so it is worth speaking with patent counsel about a filing before the fundraising process starts.
Diagram: where a startup's IP has to come from. Founders, employees, contractors and advisors assign their work in writing, a university or lab grants a license, and prior employer agreements are checked, so the company owns or can use its core technology.

Gaps here are fixable, but they are much easier to fix before a term sheet than during diligence, when a missing signature from a departed co-founder or a former contractor can hold up a closing.

University and lab licenses

Many deep tech and life sciences companies start from research owned by a university, hospital or national lab. In that case the company does not own its core patents. It licenses them, and the license becomes one of the most important documents in the seed round. Investors will read it closely, and its terms follow the company through every later round and any acquisition.

Terms that deserve attention before you sign:

  • Exclusivity and field of use. Whether the license is exclusive, and whether it covers every application of the technology or only a defined field. A narrow field can limit where the company is able to go later.
  • Financial terms. Upfront fees, royalties on sales, milestone payments, and a share of any sublicensing income. Many universities also take an equity stake, sometimes with protection against dilution until the company has raised a set amount.
  • Diligence milestones. Deadlines for raising money or reaching development stages. Missing them can allow the institution to terminate the license or make it non-exclusive.
  • Patent costs and control. Who pays for filing and maintaining the patents, and who decides how they are prosecuted and enforced.
  • Sublicensing and assignment. Whether the company can sublicense to partners, and whether the license transfers if the company is acquired. An acquirer will check.
  • Government rights. If the research was federally funded, the Bayh-Dole Act generally lets the institution keep title, but the government retains a license to use the invention and certain other rights, including a requirement that products sold in the United States under an exclusive license be substantially manufactured there unless a waiver is granted.

Some companies raise their seed round holding only an option or a term sheet from the technology transfer office. That can work, but most investors will want the license signed, or close to it, before they close.

Grants and venture money

Deep tech companies often fund early work with grants, such as the federal SBIR and STTR programs, alongside or ahead of venture capital. Grant money does not dilute the founders, which makes it attractive. It does come with terms, and those terms interact with a venture round in ways worth checking in advance.

  • Rights in what you invent. Inventions made with federal funding typically have to be reported to the agency, and the government keeps a license to use them. Missing the reporting steps can put the company's rights at risk.
  • Eligibility. Programs such as SBIR have ownership and size requirements. A venture round can change who owns the company enough to affect whether it still qualifies, and the rules differ by agency.
  • Use of funds. Grant budgets are restricted to the funded project and are subject to audit. Investors will want to see that grant money and investor money have been tracked separately.

None of this argues against grants. It means the grant terms belong in the same review as the financing documents, so that one does not undercut the other.

Software seed and deep tech seed, side by side

Typical software seed vs. deep tech seed
Software seedDeep tech or life sciences seed
What investors underwriteUsers, retention, early revenueTechnical milestones and evidence the technology works
Main diligence focusCap table, contracts, growth metricsIP ownership, licenses, freedom to operate, grant terms
Where the IP comes fromUsually written by the founding teamOften a university, lab or prior employer
What the round pays forHiring and go-to-marketR&D, equipment, prototypes, studies
Time to the next roundOften 18 to 24 monthsSet by the next milestone, and often longer
Other fundingRareGrants and strategic partners are common
Outside rulesMostly privacy and commercial lawMay include FDA, export controls, foreign investment review

Structuring the round

The instruments are the same ones every startup uses. A SAFE defers the valuation question and is quick to sign. A priced round sells preferred stock at an agreed valuation and brings a board seat, investor vetoes and the rest of the governance terms with it. Our guide to what changes between a SAFE and a priced round covers the mechanics. A few points come up more often in deep tech:

  • Round size and stacking. Deep tech seeds are often larger, and many companies raise several SAFEs over a long pre-seed period before a priced round. Each SAFE converts into its own percentage of the company, so it is worth modeling all of them converting together before signing the next one.
  • Tranches. Some investors propose releasing part of the money only when a milestone is met. That moves risk from the investor to the company. If a tranche is on the table, the definition of the milestone, who decides whether it was met, and what happens if the investor declines to fund the second closing all need careful drafting.
  • Strategic investors. A corporate investor can bring manufacturing, distribution or regulatory expertise. It may also ask for commercial rights alongside its shares, such as a right of first negotiation on a license or acquisition. Rights like these can discourage other partners and acquirers later, so they should be weighed as business terms, not treated as boilerplate.
  • The board. A technical founding team and an investor director will need to make decisions together for a long time. Our guide to startup board governance from seed to Series C covers how seats and vetoes usually develop.
  • The option pool. Specialist hires are expensive, and investors will usually ask for the pool to be sized before the round. The size is a negotiated number based on a real hiring plan.

Pulled together, the preparation looks like this:

Deep tech seed checklist
Before investor conversations start

Regulatory questions that reach the term sheet

Depending on the technology, regulation can shape both the milestones and the investor list.

  • Product approval. For drugs, devices and diagnostics, the regulatory pathway largely defines the milestones investors fund, and the use of proceeds should line up with it.
  • Export controls. Some technologies, including certain robotics, aerospace, semiconductor and encryption work, are subject to U.S. export control rules. These can restrict what may be shared with foreign nationals, including employees and prospective investors, without a license.
  • Foreign investment review. Investments by foreign persons in U.S. companies working with certain critical technologies can be subject to review by the Committee on Foreign Investment in the United States, and some require a filing before closing. If a foreign fund or strategic investor is in the round, raise this with counsel early.

What to ask seed counsel

General criteria for choosing a financing lawyer are covered in our guide on how to choose a lawyer for your seed or Series A round. For a deep tech company, add these:

  • Have you closed venture financings for companies whose core technology is licensed from a university or lab?
  • Will you review our IP assignments and any license before we start investor conversations, and tell us what an investor's lawyer is likely to flag?
  • Have you worked on both the company side and the investor side of a financing?
  • Who will actually do the work on our round, and who do we call with questions?
  • How do you work with patent counsel? Corporate counsel and patent counsel are usually different people, and they need to coordinate.
  • How do you bill for a financing, and what would ongoing support look like after it closes?

Legal support after the round

Closing the seed round starts a steady stream of legal work: board meetings and consents, option grants, employment and contractor agreements, lab or facility leases, research collaborations, material transfer agreements, supplier contracts, and keeping the license and any grants in good standing.

There are two common ways to pay for it. Outside counsel billed hourly suits companies whose needs come in bursts. Fractional general counsel, at a fixed monthly fee scoped to the company, suits companies with a predictable flow of work that want one lawyer who knows the business and sits close to its decisions. Neither is right for every company, and the answer can change as the company grows.

Where Founders Form fits

Founders Form is a law firm in Palo Alto for venture-backable startups, including deep tech and life sciences companies. It handles fundraising from SAFEs through Series C and works with funded companies as outside general counsel afterward. Omed Sharifi, who leads the firm, practiced at Cooley, Fenwick & West and Morrison & Foerster before founding it, has represented both companies and venture funds, and works directly with founders rather than through a rotating team.

Legal work is billed hourly, and fractional general counsel is available at a fixed monthly fee scoped to each company. The fundraising work is described on the startups raising capital page, and ongoing support after the round on the outside general counsel page.

This article is general information about startup financing, not legal advice about your company's situation. Intellectual property, licensing, grant and regulatory rules depend on your specific facts and agreements, and speaking with a lawyer about them is the only way to know how they apply to you.